Evecxia

Evecxia is a small biotechnology company located in Durham, North Carolina, with a team of four employees. Evecxia focuses on developing novel therapeutics for brain disorders by leveraging the power of serotonin synthesis amplification. Their approach, distinct from traditional methods like SSRIs and psilocybin, utilizes 5-HTP, a natural serotonin precursor, delivered through proprietary drug delivery technologies. This method aims to achieve sustained serotonin synthesis amplification, a key target in their drug development pipeline. The company currently has two Phase 2 clinical-stage drug candidates in development. EVX-101 is being investigated as an adjunctive treatment for depression in patients who haven't responded adequately to initial SSRI/SNRI antidepressant therapies. EVX-301 is being explored as a rescue therapy for individuals experiencing acute suicidal ideation. Evecxia holds a strong intellectual property portfolio, encompassing patents related to their 5-HTP sustained-release method, dosages, formulations, and associated technologies. For more information about Evecxia and their groundbreaking research, please visit their website at evecxia.com.